Delving into the Latest Updates on Pranlukast Hydrate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Azlaire, Dolukast hydrate, PLK-DS

+ [16]

Target

CysLT

Mechanism

CysLT antagonists(Cysteinyl leukotriene receptor antagonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesOtorhinolaryngologic Diseases+ [1]

Active Indication

Rhinitis, Allergic, PerennialRhinitis, AllergicAsthma

Inactive Indication

Chronic sinusitis

Originator Organization

Ono Pharmaceutical Co., Ltd.

Active Organization

Ono Pharmaceutical Co., Ltd.Sam-A Pharm Co., Ltd.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (31 Mar 1995),

Asthma

Regulation-

Login to view timeline

Structure

Molecular FormulaC27H23N5O4

InChIKeyNBQKINXMPLXUET-UHFFFAOYSA-N

CAS Registry103177-37-3

View All Structures (2)

主要研究目的：按有关生物等效性试验的规定，选择小野药品工业株式会社为持证商的普仑司特干糖浆剂（商品名：ONON®Dry Syrup 10％，规格:70mg/0.7g（10%））为参比制剂，对济川药业集团有限公司研制的受试制剂普仑司特干糖浆（规格：70mg）进行空腹和餐后给药状态下人体生物等效性试验，评估受试制剂和参比制剂在空腹及餐后状态下给药时的生物等效性。次要研究目的：观察健康志愿受试者口服受试制剂普仑司特干糖浆（规格：70mg）和参比制剂普仑司特干糖浆剂（商品名：ONON®Dry Syrup 10％，规格: 70mg/0.7g（10%））的安全性。

[Translation]

Main research purpose: According to the relevant provisions of bioequivalence test, the pranlukast dry syrup (trade name: ONON®Dry Syrup 10%, specification: 70mg/0.7g (10%)) of Ono Pharmaceutical Co., Ltd. was selected as the reference preparation, and the human bioequivalence test of the test preparation pranlukast dry syrup (specification: 70mg) developed by Jichuan Pharmaceutical Group Co., Ltd. was conducted under fasting and postprandial administration to evaluate the bioequivalence of the test preparation and the reference preparation when administered under fasting and postprandial conditions. Secondary research purpose: To observe the safety of oral administration of the test preparation pranlukast dry syrup (specification: 70mg) and the reference preparation pranlukast dry syrup (trade name: ONON®Dry Syrup 10%, specification: 70mg/0.7g (10%)) by healthy volunteers.

Start Date05 Jul 2023

Sponsor / Collaborator

Jumpcan Pharmaceutical Co. Ltd.

NCT03826485 / Unknown statusPhase 1

A Randomized, Open-label, Single-dose, Crossover Study to Compare Pharmacokinetics of PRIC and Pranlukast Dry Syrup in Healthy Male Volunteers

The purpose of this study is Safety, Pharmacokinetic Study of PRIC

Start Date01 Apr 2019

Sponsor / Collaborator

SAMA Pharma Co. Ltd.

JPRN-UMIN000025608 / RecruitingIIT

A prospective multicenter study of the efficacy of pranlukast hydrate for infant patients with acute wheezing illness caused by RS virus infection - A prospective multicenter study of the efficacy of pranlukast hydrate for infant patients with acute wheezing illness caused by RS virus infection

Start Date01 Mar 2017

Sponsor / Collaborator

Nagoya University Hospital

100 Clinical Results associated with Pranlukast Hydrate

Login to view more data

100 Translational Medicine associated with Pranlukast Hydrate

Login to view more data

100 Patents (Medical) associated with Pranlukast Hydrate

Login to view more data

449

Literatures (Medical) associated with Pranlukast Hydrate

01 Sep 2024·The Journal of Allergy and Clinical Immunology: In Practice

Neuropsychiatric Events Related to Montelukast and Pranlukast in Adults With Asthma and Rhinitis: A 10-Year Nationwide Population-Based Study

Article

Author: Her, Young ; Kwon, Hyouk-Soo ; Kwon, Jae-Woo ; Min, Joonhong ; Jo, Young-Woo

BACKGROUNDEpidemiological studies of neuropsychiatric events (NPEs) associated with leukotriene receptor antagonists (LTRAs) have yielded inconsistent results. Recent studies have demonstrated strong temporal relationships between LTRA prescription and NPE occurrence, indicating a need for further investigation.OBJECTIVETo investigate potential LTRA-related NPEs and associated risk factors.METHODSAdults with asthma or rhinitis were enrolled from the Korean claims database. The temporal relationship between the first NPE diagnosis and the last LTRA prescription before NPE was evaluated. Nested case-control studies for NPEs and suicide were conducted. Cases (those with NPEs) were matched to controls for age and sex to compare the frequency of LTRA prescription in the lag time before NPE diagnosis. The risk factors for LTRA-related NPEs (developed within 6 months of LTRA prescription) were assessed in people on LTRAs by comparing those with LTRA-related NPEs to those on LTRAs who did not have NPEs.RESULTSMontelukast and pranlukast were more frequently prescribed within 6 months before NPEs (odds ratio, 1.31, 95% CI, 1.21-1.41, and odds ratio, 1.25, 95% CI, 1.15-1.35). Older adults, low income, high comorbidity burden, and asthma exhibited stronger associations with LTRA-related NPEs than with general NPEs. Sleep disturbances appeared more prevalent in LTRA-related NPEs than in other NPEs. An LTRA prescription within 6 months was associated with suicide in univariate but not in multivariate analysis.CONCLUSIONSIncreased neuropsychiatric risk was observed within 6 months after LTRA prescription. LTRA may lower the threshold for NPEs in those at risk for NPEs, irrespective of sex.

01 Sep 2024·Medicinal Research Reviews

Benzopyrone, a privileged scaffold in drug discovery: An overview of FDA‐approved drugs and clinical candidates

Review

Author: Sharma, Ankita ; Bharate, Sandip B. ; Wadje, Bhagyashri N ; Bharate, Sandip B ; Wadje, Bhagyashri N. ; Sharma, Venu

AbstractNatural products have always served as an important source of drugs for treating various diseases. Among various privileged natural product scaffolds, the benzopyrone class of compounds has a substantial presence among biologically active compounds. One of the pioneering anticoagulant drugs, warfarin approved in 1954 bears a benzo‐α‐pyrone (coumarin) nucleus. The widely investigated psoriasis drugs, methoxsalen, and trioxsalen, also contain a benzo‐α‐pyrone nucleus. Benzo‐γ‐pyrone (chromone) containing drugs, cromoglic acid, and pranlukast were approved as treatments for asthma in 1982 and 2007, respectively. Numerous other small molecules with a benzopyrone core are under clinical investigation. The present review discusses the discovery, absorption, distribution, metabolism, excretion properties, and synthetic approaches for the Food and Drug Administration‐approved and clinical‐stage benzopyrone class of compounds. The role of the pyrone core in biological activity has also been discussed. The present review unravels the potential of benzopyrone core in medicinal chemistry and drug development.

01 Jul 2024·Journal of Chromatography A

Site-specific immobilization of Cysteinyl leukotriene receptor 1 through enzymatic DNA-protein conjugation strategy for lead screening

Article

Author: Wen, Xin ; Zhao, Xinfeng ; Li, Zimeng ; Xu, Ke ; Liu, Weiyao ; Wang, Jing ; Chen, Minyu

Immobilization of functional protein, especially G protein-coupled receptors (GPCRs), is particularly significant in various fields such as the development of assays for diagnosis, lead compound screening, as well as drug-protein interaction analysis. However, there are still some challenges with the immobilized proteins such as undefined loads, orientations, and the loss of activity. Herein, we introduced a DNA conjugation strategy into the immobilization of Cysteinyl leukotriene receptor 1(CysLTR1) which enables exquisite molecular control and higher activity of the receptor. We used the bacterial relaxases VirD2 as an immobilized tag fused at the C terminus of CysLTR1. Tyrosine residue(Y29) at the core binding site of the VirD2 tag can react with the single-strand piece of DNA(T-DNA) in the form of a covalent bond. Inspired by this strategy, we developed a new immobilization method by mixing the T-DNA-modified silica gel with the cell lysate containing the expressed VirD2-tagged CysLTR1 for 1 hour. We found that the successful formation of DNA-protein conjugate enables the immobilization of CysLTR1 fast, site-specific, and with minimal loss of activity. The feasibility of the immobilized CysLTR1 was evaluated in drug-protein binding interaction by frontal analysis and adsorption energy distribution analysis. The binding of pranlukast, zafirlukast, and MK571 to the immobilized CysLTR1 was realized, and the association constants presented good agreement between the two methods. Rosmarinic acid was retained in the immobilized CysLTR1 column, and the in-vitro test revealed that the compound binds to the receptor in one type of binding site mode. Despite these results, we concluded that the DNA-protein conjugate strategy will probably open up the possibilities for capturing other functional proteins in covalent and site-specific modes from the complex matrices and the immobilized receptor preserves the potential in fishing out lead compounds from natural products.

100 Deals associated with Pranlukast Hydrate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02732	Pranlukast Hydrate	R03DC02	DB01411

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Rhinitis, Allergic, Perennial	KR	Sam-A Pharm Co., Ltd.	14 Aug 2024
Rhinitis, Allergic	JP	Ono Pharmaceutical Co., Ltd.	08 Jan 2000
Asthma	JP	Ono Pharmaceutical Co., Ltd.	31 Mar 1995